Comparative Effectiveness and Safety of Atezolizumab–Bevacizumab and Durvalumab–Tremelimumab as First‐Line Systemic Therapy for Hepatocellular Carcinoma: A Real‐World Study

Journal of Gastroenterology and Hepatology (Australia) · Published 2026-07-10 · DOI 10.1111/jgh.70555

Free full text

Authors (6)

Shu Hsien Lin, Jia‐Ling Wu, Ying‐Nan Tsai, Cheng‐Hao Tseng, Po‐Yueh Chen, Yao‐Chun Hsu

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Lin, S., Wu, J., Tsai, Y., et al. (2026). Comparative Effectiveness and Safety of Atezolizumab–Bevacizumab and Durvalumab–Tremelimumab as First‐Line Systemic Therapy for Hepatocellular Carcinoma: A Real‐World Study. Journal of Gastroenterology and Hepatology (Australia). https://doi.org/10.1111/jgh.70555

Related articles